Clinical trials: Beta-lactam Antibiotics
Pediatric Intensive Care Unit, Pediatric Immuno-hematology Department
Population Pharmacokinetics of Anti-infectives in Critically Ill Children
Concentrations and effects of anti-infectives in critically ill children are unpredictable and the risk of under-exposure may be associated with poor clinical outcomes.
- Trial name
- OPTIMOME (NCT02539407)
- Testing
- Pharmacokinetics
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bacterial Infections
Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects
QPX7728 is an ultra-broad-spectrum beta-lactamase inhibitor, with activity against numerous beta-lactamases, including class A extended spectrum betalactamases (ESBLs), class C cephalosporinases, and extended spectrum class D…
- Trial name
- NCT05072444
- Testing
- QPX7728, QPX2014
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Surgical Site Infection, Beta-lactam Allergy
Prophylactic Antibiotics for Surgical Site Infections and Beta-Lactam Allergy
Postoperative surgical site infection (SSI) is associated with unnecessary use of heath care resources including prolonged hospitalization and increased hospital readmission.
- Trial name
- NCT04401553
- Testing
- cephalosporin, Second tier antibiotic (Vancomycin)
- Sponsor
- University of Texas Southwestern Medical Center
Infection
Does a Safety Difference Exist Between IV Push and IV Piggyback Antibiotics?
This study compares whether or not a safety difference exists between delivering antibiotics via IV push or IV piggyback method.
- Trial name
- IVP-ABX (NCT03360617)
- Testing
- Syringe IV Push over 2-3 minutes, Piggyback over 30 minutes
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University Medical Center of Southern Nevada
Community-acquired Pneumonia
Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia
The purpose of this study is to determine whether a monotherapy with a Beta-Lactam is not inferior to an association of a Beta-Lactam and a macrolide in treating adult patients with community-acquired pneumonia.
- Trial name
- BICAP (NCT00818610)
- Testing
- Beta lactam (amoxicillin / clav. acid OR cefuroxime), Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)
- Where
- 6 sites in Switzerland
- Volunteers
- 601 people
- Sponsor
- Swiss National Fund for Scientific Research
Sepsis
Beta-Lactam InfusioN Group Study
The purpose of this study is to find out whether continuous infusion of beta-lactam antibiotics or intermittent infusion or beta-lactam antibiotics, offers more health advantages to patients or if there is no difference.
- Trial name
- BLING III (NCT03213990)
- Testing
- Continuous infusion, Intermittent infusion
- Where
- 103 sites in Australia, Belgium and 5 more
- Volunteers
- 7,203 people
- Sponsor
- The George Institute
Beta-lactam, Continuous Renal Replacement Therapy
Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study
Pneumonia are the most frequent infections in ICU. Little is known about beta-lactam doses necessary for this infection for patients treated with continuous veino-veinous hemodialysis.
- Conditions
- Beta-lactam, Continuous Renal Replacement Therapy, Pneumonia, Antibiotic
- Trial name
- BLIPIC (NCT03897582)
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Centre Hospitalier de Valenciennes
Bacterial Infections
Phase 1 Study of Oral QPX2015 in Healthy Adult Subjects
QPX2015 (beta-lactam antibiotic) is being studied at higher than approved doses to combine with a new beta-lactamase inhibitor to treat bacterial infections, including those due to multi-drug resistant bacteria.
- Trial name
- NCT03939429
- Testing
- QPX2015
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Bacterial Infection
Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)
This is a Phase 4, interventional, multi-center pharmacokinetics (PK) study in up to 200 adult patients who are residing in an ICU.
- Trial name
- NCT06709521
- Testing
- Iohexol
- Where
- 10 sites in United States
- Volunteers
- 161 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Allergy
Negative Predictive Value and NIC of Beta-Lactam Antibiotics.
The researchers are trying to evaluate how much medication is required for allergy skin testing and to determine the likelihood that patients with a negative test truly don't have an allergy to the tested drug of skin testing to…
- Trial name
- NCT04126096
- Testing
- Skin Testing beta-lactams
- Where
- 2 sites in United States
- Volunteers
- 747 people
- Sponsor
- Mayo Clinic
Sepsis, Hemodynamic Instability
Therapeutic Drug Monitoring in Patients With Difficult-to-Treat Gram-Negative Bacterial Infections
A prospective, open-label, randomized controlled trial will be conducted to evaluate a novel TDM-guided therapy in management of DT-GNB infections.
- Conditions
- Sepsis, Hemodynamic Instability, Bacterial Infections, Therapeutic Drug Monitoring
- Trial name
- TDM-RCT (NCT05942157)
- Testing
- Therapeutic Drug Monitoring (TDM)
- Where
- Singapore
- Volunteers
- 810 people
- Sponsor
- Singapore General Hospital
Penicillin Allergy, In-hospital Process Optimization
A Digital Stewardship Strategy for Patients With Reported Penicillin Allergy
The goal of this clinical study is to evaluate whether a digital decision support tool integrated into the electronic medical record improves antibiotic prescribing in hospitalized patients with a reported allergy to penicillin.
- Trial name
- Digitalpen (NCT07604597)
- Where
- Spain
- Volunteers
- 182 people
- Sponsor
- Althaia Xarxa Assistencial Universitària de Manresa
Bacterial Infections
Personalized Antibiotic Therapy - Point-of-Care Determination of Blood Levels of Beta-Lactam Antibiotics Using Coated-Blade-Spray Ion Mobility Spectrometry
A new analytical method for determining beta-lactam antibiotic concentrations in the blood of intensive care patients is to be evaluated.
- Trial name
- CBS-IMS (NCT07666230)
- Volunteers
- 200 people
- Sponsor
- Dr. T. Perl
Infection, Bacterial, Beta-lactam Antibiotics
External Validation of the Beta-lactam Target Non-attainment (BATMAN) Risk Score in Adult ICU Patients: a Diagnostic Multivariate Predictive Risk Model
Intensive care (IC) patients regularly get infections. Sometimes it is even the reason of admission to the intensive care unit. To treat these infections, we give medicines called antibiotics, such as β-lactams antibiotics.
- Conditions
- Infection, Bacterial, Beta-lactam Antibiotics, Critical Care, Risk Model
- Trial name
- BATMAN (NCT05542771)
- Where
- 6 sites in Netherlands
- Volunteers
- 130 people
- Sponsor
- Chantal Kats
Sepsis
The Distribution of Plasma Drug Concentrations of Beta-lactam Antibiotics in Intensive Care Unit Patients
In this project, intensive care unit (ICU) patients treated with beta-lactam antibiotics are included with the aim to investigate the potential underdosing in this patient group.
- Trial name
- TDM-ICU (NCT02446392)
- Testing
- No intervention.
- Where
- 4 sites in Sweden
- Volunteers
- 120 people
- Sponsor
- Linkoeping University
Critical Illness
Glycocalyx Damage and Beta-lactam Antibiotics in Surgical Critically Ill
GCX damage and its relationship to pharmacodynamics and pharmacokinetics of beta lactam antibiotics in critically ill Hypothesis to be tested: GCX damage impairs pharmacodynamics and pharmacokinetics of beta-lactam antibiotics in…
- Trial name
- NCT03136796
- Testing
- Meropenem
- Where
- Czechia
- Volunteers
- 20 people
- Sponsor
- University Hospital Hradec Kralove
Infection
Pharmacokinetics of Small Spectrum Beta-lactam Antibiotics (Amoxicillin/Clavulanic Acid and Cefuroxime) in Patients on Intensive Care Units
Adequate antibiotic therapy is very important in the treatment of infections. Spectrum and dosing of the antibiotics are two factors of the therapy: the spectrum of an antibiotic can't be changed, but the dosing scheme can be…
- Trial name
- AMOCEF (NCT01581047)
- Where
- Belgium
- Volunteers
- 37 people
- Sponsor
- University Hospital, Ghent
Sepsis - to Reduce Mortality in the Intensive Care Unit, Sepsis
Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis
The aim of this study is to investigate if an initial short double dose of beta-lactam antibiotics will reduce mortality in critically ill patients with sepsis.
- Conditions
- Sepsis - to Reduce Mortality in the Intensive Care Unit, Sepsis, Septic Shock
- Trial name
- BULLSEYE (NCT06766461)
- Testing
- Double dosing of beta-lactam antibiotic
- Where
- Netherlands
- Volunteers
- 980 people
- Sponsor
- Erasmus Medical Center
Bacterial Infections
P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV
QPX7728 is an ultra-broad-spectrum beta-lactamase inhibitor, with activity against numerous beta-lactamases, including class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and extended spectrum class D…
- Trial name
- NCT04380207
- Testing
- QPX7728, QPX2014
- Where
- 2 sites in United States, Australia
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Sepsis
Prolonged Intravenous Infusion of β-lactam Antibiotics in Early Septic Patients
The prolonged β-lactam Antibiotics intravenous infusion strategy has emerged as the standard treatment for sepsis despite its unknown efficacy.
- Trial name
- PROBES (NCT05024565)
- Testing
- prolonged intravenous infusion of β-lactams Antibiotics
- Volunteers
- 2,600 people
- Sponsor
- Qilu Hospital of Shandong University